(4-032) Efficacy and Safety of Investigational Microbiota-based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection from 5 Prospective Clinical Studies: An Update

Monday, December 5, 2022

2:00 PM – 3:30 PM

Location: Bayside A, Level 1

Category: Evaluative Study
Topic: Infectious Diseases/HIV

Co-Author(s): Beth Guthmueller, Lindy Bancke

Primary Author(s)

Adam Harvey, PhD
Principal Clinical Research Scientist
Rebiotix Inc., a Ferring Company, Minnesota